Dr. Reddy’s announced the launch of AVIGAN (Favipiravir) 200 mg Tablets in India. The launch is part of the global licensing agreement with FUJIFILM Toyama Chemical Co. Ltd. that grants Dr. Reddy’s the exclusive rights to manufacture, sell and distribute AVIGAN (Favipiravir) 200 mg Tablets in India. AVIGAN (Favipiravir) has been approved by the Drugs…
Pharma major Lupin Limited announced the launch of its Favipiravir in India under the brand name Covihalt for the treatment of mild to moderate COVID-19. Favipiravir has received authorization from the Drug Controller General of India (DCGI) for emergency use, the company mentioned in its press note. Lupin’s Covihalt dosage strength has been developed keeping…
Cipla Limited announced that it has been granted regulatory approval by the Drug Controller General of India (DCGI) for the launch of Favipiravir in the country under the brand name Ciplenza. The accelerated approval for manufacturing and marketing of the drug is aimed at meeting the urgent and unmet medical need for COVID-19 treatment options…
Glenmark Pharmaceuticals, a research-led, integrated global pharmaceutical company, announced that it has commenced a Post Marketing Surveillance (PMS) study on FabiFlu to closely monitor the efficacy and safety of the drug in 1000 patients that are prescribed with the oral antiviral, as part of an open label, multicenter, single arm study. Further, Glenmark has announced…
Sun Pharmaceutical Industries Ltd, a Mumbai-based generic pharmaceutical company, announced that it has commenced Phase II clinical trial on AQCH, a phytopharmaceutical (plant derived) drug for treatment of COVID-19. The Company received approval from the Drugs Controller General of India (DCGI) for conducting Phase II clinical trials in April this year. The clinical trial will…